University of Hertfordshire

Standard

A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD. / Biria, Marjan; Huang, Fiona-Xiaofei; Worbe, Yulia; Fineberg, Naomi; Robbins, Trevor W.; Fernandez-Egea, Emilio.

In: European Neuropsychopharmacology, 11.06.2019.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Biria, Marjan ; Huang, Fiona-Xiaofei ; Worbe, Yulia ; Fineberg, Naomi ; Robbins, Trevor W. ; Fernandez-Egea, Emilio. / A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD. In: European Neuropsychopharmacology. 2019.

Bibtex

@article{11eb1cf287744751bf81ee0d98f1937e,
title = "A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD",
abstract = "A large proportion of schizophrenia patients treated with second generation antipsychotics will develop Obsessive Compulsive Disorder (OCD). However, there are few studies about the impact of this comorbidity and who is at higher risk. In this study of clozapine-treated patients, we aimed to determine the impact on outcome of clozapine-induced OCD, as well as the clinical and sociodemographic risk factors related to OCD-onset in clozapine patients. We had strict and novel inclusion criteria to minimise mid-identification of cases. The Obsessive-Compulsive Inventory-Revised (OCI-R) was used to divide 231 clozapine-treated patients into extreme cases of OCD (OCI ≥24 or checking subscale ≥6) versus non-OCD (OCI <15 and checking subscale <4). The Global Assessment of Functioning (GAF), short version of Warwick-Edinburgh Wellbeing scale and Clinical Global Impression for schizophrenia (CGI) scales were used to determine outcome. Socio-demographic information was used to identify the risk factors for OCD development. We found that schizophrenia patients with OCD symptoms had a significantly lower patient rated wellbeing scores (p<0.001) only (no difference in clinician rated wellbeing scores), higher CGI positive (p<0.01) and higher CGI depressive scores (p<0.05). The only risk factor that reached significance level was younger paternal age at birth (p<0.05). There is scope for future studies based on e.g. imaging and genetic studies to further investigate causality, and in improving clinician screening for OCD.",
author = "Marjan Biria and Fiona-Xiaofei Huang and Yulia Worbe and Naomi Fineberg and Robbins, {Trevor W.} and Emilio Fernandez-Egea",
year = "2019",
month = "6",
day = "11",
doi = "https://doi.org/10.1016/j.euroneuro.2019.06.006",
language = "English",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD

AU - Biria, Marjan

AU - Huang, Fiona-Xiaofei

AU - Worbe, Yulia

AU - Fineberg, Naomi

AU - Robbins, Trevor W.

AU - Fernandez-Egea, Emilio

PY - 2019/6/11

Y1 - 2019/6/11

N2 - A large proportion of schizophrenia patients treated with second generation antipsychotics will develop Obsessive Compulsive Disorder (OCD). However, there are few studies about the impact of this comorbidity and who is at higher risk. In this study of clozapine-treated patients, we aimed to determine the impact on outcome of clozapine-induced OCD, as well as the clinical and sociodemographic risk factors related to OCD-onset in clozapine patients. We had strict and novel inclusion criteria to minimise mid-identification of cases. The Obsessive-Compulsive Inventory-Revised (OCI-R) was used to divide 231 clozapine-treated patients into extreme cases of OCD (OCI ≥24 or checking subscale ≥6) versus non-OCD (OCI <15 and checking subscale <4). The Global Assessment of Functioning (GAF), short version of Warwick-Edinburgh Wellbeing scale and Clinical Global Impression for schizophrenia (CGI) scales were used to determine outcome. Socio-demographic information was used to identify the risk factors for OCD development. We found that schizophrenia patients with OCD symptoms had a significantly lower patient rated wellbeing scores (p<0.001) only (no difference in clinician rated wellbeing scores), higher CGI positive (p<0.01) and higher CGI depressive scores (p<0.05). The only risk factor that reached significance level was younger paternal age at birth (p<0.05). There is scope for future studies based on e.g. imaging and genetic studies to further investigate causality, and in improving clinician screening for OCD.

AB - A large proportion of schizophrenia patients treated with second generation antipsychotics will develop Obsessive Compulsive Disorder (OCD). However, there are few studies about the impact of this comorbidity and who is at higher risk. In this study of clozapine-treated patients, we aimed to determine the impact on outcome of clozapine-induced OCD, as well as the clinical and sociodemographic risk factors related to OCD-onset in clozapine patients. We had strict and novel inclusion criteria to minimise mid-identification of cases. The Obsessive-Compulsive Inventory-Revised (OCI-R) was used to divide 231 clozapine-treated patients into extreme cases of OCD (OCI ≥24 or checking subscale ≥6) versus non-OCD (OCI <15 and checking subscale <4). The Global Assessment of Functioning (GAF), short version of Warwick-Edinburgh Wellbeing scale and Clinical Global Impression for schizophrenia (CGI) scales were used to determine outcome. Socio-demographic information was used to identify the risk factors for OCD development. We found that schizophrenia patients with OCD symptoms had a significantly lower patient rated wellbeing scores (p<0.001) only (no difference in clinician rated wellbeing scores), higher CGI positive (p<0.01) and higher CGI depressive scores (p<0.05). The only risk factor that reached significance level was younger paternal age at birth (p<0.05). There is scope for future studies based on e.g. imaging and genetic studies to further investigate causality, and in improving clinician screening for OCD.

U2 - https://doi.org/10.1016/j.euroneuro.2019.06.006

DO - https://doi.org/10.1016/j.euroneuro.2019.06.006

M3 - Article

JO - European Neuropsychopharmacology

T2 - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

ER -